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AbstrACt
Introduction Social prescribing enables healthcare 
professionals to use voluntary and community sector 
resources to improve support for people with long-
term conditions. It is widely promoted in the UK as 
a way to address complex health, psychological and 
social issues presented in primary care, yet there is 
insufficient evidence of effectiveness or value for money. 
This study aims to evaluate the impact and costs of 
a link-worker social prescribing intervention on the 
health and healthcare use of adults aged 40–74 with 
type 2 diabetes, living in a multi-ethnic area of high 
socioeconomic deprivation.
Methods and analysis Mixed-methods approach 
combining (1) quantitative quasi-experimental methods 
to evaluate the effects of social prescribing on health 
and healthcare use and cost-effectiveness analysis and 
(2) qualitative ethnographic methods to observe how 
patients engage with social prescribing. Quantitative 
data comprise Secondary Uses Service data and Quality 
Outcomes Framework data. The primary outcome is 
glycated haemoglobin, and secondary outcomes are 
secondary care use, systolic blood pressure, weight/
body mass index, cholesterol and smoking status; 
these data will be analysed longitudinally over 3 years 
using four different control conditions to estimate 
a range of treatment effects. The ranges where the 
intervention is cost-effective will be identified from the 
perspective of the healthcare provider. Qualitative data 
comprise participant observation and interviews with 
purposively sampled service users, and focus groups 
with link-workers (intervention providers). Analysis 
will involve identification of themes and synthesising 
and theorising the data. Finally, a coding matrix will 
identify convergence and divergence among all study 
components.
Ethics and dissemination UK NHS Integrated Research 
Approval System Ethics approved the quantitative 
research (Reference no. 18/LO/0631). Durham 
University Research Ethics Committee approved the 
qualitative research. The authors will publish the 
findings in peer-reviewed journals and disseminate to 
practitioners, service users and commissioners via a 
number of channels including professional and patient 
networks, conferences and social media. Results will be 
disseminated via peer-reviewed journals.
bACkground 
Social prescribing enables healthcare profes-
sionals to address non-medical causes of 
ill-health through using the resources of the 
voluntary and community sectors.1 Social 
prescribing is widely promoted in the UK as 
a way of addressing complex health, psycho-
logical and social issues presented in primary 
care,2 improving support for people with long-
term conditions and making general practice 
more sustainable.3 It is also viewed as an inter-
vention with the potential to reduce health 
inequalities.2 3 There is no agreed definition 
and no single model of social prescribing. 
However, typically social prescribing for 
people with long-term conditions harnesses 
voluntary and community sector assets 
strengths and limitations of this study
 ► This study addresses the current evidence gap 
regarding the impact and value for money of a 
link-worker social prescribing intervention.
 ► This is the first study to combine natural experimen-
tal methods, economic assessment and ethnogra-
phy to measure the impact of social prescribing.
 ► This study is timely and relevant to patients with 
type 2 diabetes, the NHS and the voluntary and 
community sectors.
 ► The focus on type 2 diabetes enables selection of 
relevant outcome measures, but limits generalis-
ability to other long-term conditions.
 ► Further challenges in generalising the findings arise 
because social prescribing models vary in terms of 
commissioning, funding, referral criteria and path-
way, service provider and the range of ‘prescribed’ 
activities.
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to encourage self-care and facilitate health-creating 
communities.2–4 To encourage engagement, most social 
prescribing schemes involve a facilitator ‘link-worker’ 
who supports service users to identify and achieve person-
alised condition management and behaviour change 
goals.5 
There is considerable support at policy level in the 
UK for social prescribing6 7 and the UK’s Department 
of Health recently pledged £4.5 million towards social 
prescribing in primary care.8 However, a systematic 
review of the effectiveness of social prescribing inter-
ventions9 concluded that there is currently insufficient 
robust evidence of effectiveness or value for money. This 
review reinforces the conclusions of three non-systematic 
reviews advocating that evaluations of community-based 
social prescribing require control groups, larger sample 
sizes, longer-term follow-up and clinically meaningful 
outcome measures.4 10 11
Of the two most robust studies available, the first 
published in 200012 (included in Bickerdike et al’s system-
atic review) was conducted in England and comprised a 
randomised controlled trial (RCT) of a link-worker inter-
vention for primary care patients (aged 16 years and over) 
with psychosocial problems. Four months after randomi-
sation, significant improvements were found for anxiety 
and some aspects of quality of life, but no effects were 
found for depression, social isolation, general practitioner 
(GP) consultation rate or GP prescribing in a sample of 
161 patients (n=90 in the intervention group; n=71 in the 
control group). The second study13 comprised a quasi-ex-
perimental general-practice level cluster RCT with a 
mixed-methods process evaluation of a practice-based 
Community Links Practitioner social prescribing interven-
tion in 15 general practices in Scotland targeting patients 
with complex needs.13 This RCT did not find statistically 
significant differences in the primary outcome measure—
EQ-5D-5L—at 9 months compared with usual care, but 
improvements were reported in the following secondary 
outcomes: increased levels of self-reported exercise, 
reduced anxiety and depressive symptoms. There were 
no beneficial effects on self-reported healthcare use. The 
authors conclude that a longer-term outcome evaluation 
using robust routinely collected data is required.14
There is therefore an imperative to obtain robust 
evidence about the impact and cost-effectiveness of social 
prescribing.1 9 Building on recently completed quan-
titative and qualitative research,15–17 this study aims to 
evaluate the impact and costs of a community-based link-
worker social prescribing intervention on the health and 
healthcare use of adults aged 40–74 with type 2 diabetes 
(T2D), living in a multi-ethnic area of high socioeco-
nomic deprivation. Diabetes is a major public health 
issue; the number of people in the UK with this condition 
is expected to rise to over 6 million by 2035, 85–90% of 
whom have T2D. If no changes are made to the treatment 
of T2D, the costs to the NHS are estimated to increase 
to £17bn by 2035, with associated increases in the wider 
costs to society estimated at over £22bn.18 19 People with 
T2D often have one or more other long-term condition,20 
and T2D is often associated with mental health condi-
tions, such as anxiety and depression, which can nega-
tively affect an individual’s ability to manage their T2D 
and other long-term conditions.21
The study takes a mixed-methods approach combining 
quantitative quasi-experimental methods to evaluate the 
effects of social prescribing on health and healthcare use 
and qualitative ethnographic methods to observe how 
patients engage with social prescribing and the range of 
its impacts on patients and their wider social networks. A 
cost-effectiveness analysis will also be undertaken.
This study aims to answer the following questions:
1. Does a link-worker social prescribing intervention tar-
geting adults aged 40–74 with T2D result in changes 
to glycated haemoglobin (HbA1c), body mass index 
(BMI), systolic blood pressure, cholesterol, smoking, 
EQ-5D-5L and healthcare use from baseline to 12 
months?
2. Does the intervention demonstrate greater effective-
ness in subgroups (gender, age, and ethnicity) of the 
eligible population?
3. Does the intervention lead to improved health-related 
quality of life (measured by EQ-5D-5L) at 12 months?
4. How cost-effective is a link-worker social prescribing in-
tervention targeting adults aged 40–74 with T2D?
5. How does link-worker social prescribing lead to chang-
es in the daily lives of individuals, their families and 
wider social networks?
6. To what extent does link-worker social prescribing re-
duce health inequalities?
Intervention and study setting
‘Ways to Wellness’ (http:// waystowellness. org. uk/) 
delivers link-worker social prescribing to people aged 
40–74 with at least one of eight long-term conditions. It is 
based on extensive pilot work and the social prescribing 
model comprises community-based link-workers who 
deliver the intervention. Box 1 summarises the range and 
scope of the intervention.
The setting is a multi-ethnic inner-city area of high 
socioeconomic deprivation (population n=111 557), 
ranked 40th most deprived in England according to the 
Index of Multiple Deprivation.22 In the locality covered 
by the intervention, all-cause standardised mortality rates 
(<75 years) are 150, and emergency hospital admissions 
rates are 134, demonstrating considerable health disad-
vantage compared with the English standard of 100.23 
Twenty-three per cent of the population in the interven-
tion locality are from Black and minority ethnic commu-
nities compared with the Newcastle city and English 
averages of 15%.24
study population
Community-dwelling adults aged 40 to 74 years, with T2D 
with or without comorbidity or disease-related complica-
tions or a diagnosis of depression or anxiety. The inter-
vention group comprises people with T2D who meet with 
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their link-worker at least once and complete a baseline 
assessment between April 2015 and June 2018.
study design
Three separate work packages (WPs) will be undertaken, 
concluding with a fourth WP combining and integrating 
the different datasets.
Work package 1
Exploits the geographical implementation of the inter-
vention as a natural experiment. Primary and secondary 
outcomes of individuals who engage with the interven-
tion will be compared with those who are eligible but do 
not take part over 3 years from the intervention start date. 
Robustness of estimated effects will be investigated by 
exploiting a range of possible control groups (see table 1) 
and a falsification test.
Outcome measures
The primary outcome measure is HbA1c, a marker of 
blood glucose concentration. HbA1c is selected because it 
provides a good measure of T2D control, it is the diabetes 
management measure used by clinicians and is routinely 
collected in primary care.25 Secondary outcome measures 
are systolic blood pressure, weight/BMI, cholesterol and 
smoking status (all also routinely collected in primary 
care), quality of life and secondary care use.
Quality-of-life data (measured by EQ-5D-5L) are not 
routinely collected and are being collected by link-
workers. These data will provide a within-cohort compar-
ison for n=1100 individuals recruited between July 2018 
and June 2019.
Recruitment and sample size
The numbers of people with T2D who have been referred 
to the intervention are as follows: April 2015–March 2016, 
n=462; April 2016–March 2017, n=540; April 2017–March 
2018, n=600. We expect similar numbers of individuals 
for our control groups (ie, those with T2D not referred). 
With group sizes of over 1600, assuming type 1 error of 5% 
and one observation per participant, we have over 85% 
power to detect an effect size (standardised difference) 
of 0.15 in a continuous outcome and approximately 85% 
power to detect a difference of 5 percentage points in a 
binary outcome. We will cluster SEs from multiple regres-
sions on individuals and at the primary care practice level 
to acknowledge that observations are not independent 
draws from the population.
The EQ-5D-5L data will be collected for all individuals 
referred to the intervention between July 2018 and June 
2019. This gives a projected sample size of 1100 individ-
uals meaning that power will be reduced in this group. To 
detect an effect size (standardised difference) of 0.2, we 
would have a power of approximately 70%.
Research methods
Using Secondary Uses Service data and Quality Outcomes 
Framework data, linked by North of England Commis-
sioning Service, we will follow individual-level data over 
time from before the intervention period, across the 
intervention, and then for the length of the study in order 
to analyse the average treatment effect (which we call τ  ) 
of the intervention. We will apply longitudinal data anal-
ysis, taking account of individual heterogeneity, as well 
as GP, time and provider fixed effects in order to control 
for unobservables and time-invariant selection effects 
box 1 Ways to Wellness intervention
 ► Ways to Wellness (http:// waystowellness. org. uk/) is a communi-
ty-based link-worker social prescribing intervention for people 
with long-term conditions. Intervention development was based on 
extensive pilot work and co-produced with people with long-term 
conditions, over 8 years  (2007 to 2015).41–43 Ways to Wellness is 
managed via Ways to Wellness Ltd, a special-purpose vehicle set up 
to oversee the delivery of the service.
 ► The service began in April 2015 and is on target to recruit approx-
imately 1500 participants annually over 7 years (total n=10 500). 
Approximately 41% of these people have type 2 diabetes.
 ► Ways to Wellness aims to improve health-related outcomes and 
quality of life of people with long-term conditions by increasing their 
confidence and ability to manage their illness, and to reduce costs 
and/or improve value to the NHS in their treatment. The Ways to 
Wellness intervention has four key objectives: (1) to improve par-
ticipants’ health-related behaviours, (2) to improve self-care, (3) 
to encourage better long-term condition self-management and (4) 
to promote social integration. The strong focus on addressing the 
wider determinants of health through link-worker facilitated access 
to services like welfare rights, debt and housing advice and em-
ployment support emphasises the potential for the intervention to 
address health inequalities.
 ► Ways to Wellness is designed to provide an efficient referral mech-
anism for primary care practitioners,5 optimising referral practices 
through the facilitation of patients’ access to community-based 
support and social engagement, thus supplementing the care pa-
tients receive from the NHS.44 45 The Ways to Wellness intervention 
is delivered by not-for-profit organisations (originally four, now two 
organisations) allocated to geographical clusters of GP practices. 
Patients are referred by their GP to Ways to Wellness and assigned 
to a link-worker, who is a trained facilitator. Link-workers use be-
haviour change techniques including motivational interviewing, 
goal-setting and feedback to promote the aims of Ways to Wellness. 
Goal identification and setting and progress monitoring is conducted 
using the ‘Well-being Star’ 46 self-assessment tool. This proprietary 
tool helps service users to assess their state across eight parame-
ters (lifestyle; self-care; symptom management; work, volunteering 
and activity; money; home environment; personal relationships; 
positive feeling).
 ► Link-workers provide the following for each of their assigned clients: 
(a) individual assessment, motivational interviewing and action plan-
ning47; (b) completion of the ‘Well-being Star’ self-assessment tool 
at baseline and 6 monthly up to 24 months; (c) support and guidance 
to access community services (eg, walking groups, physical activ-
ity classes and welfare rights advice); (d) promotion of volunteer-
ing opportunities; (e) promotion of improved self-care. The Ways to 
Wellness intervention is highly personalised involving face-to-face 
contacts in community settings and, where necessary, domiciliary 
visits. Contact is also made, where appropriate, via email, text and 
telephone. All contacts vary in duration and frequency in accordance 
with individual client need, but overall engagement with Ways to 
Wellness can be up to 2 years.
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that may introduce bias into our estimates. Potential 
confounding variables will be included as extra controls 
where necessary. With observational data, it is often 
not possible to produce perfectly unbiased treatment 
effects.26 The best alternative is to provide a range of esti-
mated treatment effect values, with a clear explanation 
of the underlying samples from which they are derived. 
Providing bounds for the treatment effects is more infor-
mative than restricting the analysis to a single control 
group in the expectation that all of the necessary assump-
tions hold. We will estimate the appropriate models for 
outcomes (depending on whether they are continuous or 
ordinal) using difference-in-differences techniques. These 
methods will be applied to a number of control groups 
identified in table 1 to provide estimates of the treatment 
effect: τOLS (from a naive estimation); τ1, exploiting the 
timing of the intervention to provide a control group; 
and τ2, exploiting the treatment assignment rules from 
within the social prescribing providing practices to iden-
tify a control group. Further, using routinely collected data 
from GP records in the North of England Commissioning 
Service database allows us to broaden our consideration 
of the control group. Within the Newcastle uponTyne GP 
practices covered by North of England Commissioning 
Service, only 17 out of 64 are able to refer to the social 
prescribing pathway. The availability of social prescribing 
is, therefore, an exogenous event, whereby individuals are 
unable to select whether they are in a social prescribing 
referring practice (it is possible that patients could switch 
from a non-social prescribing GP practice to a referring 
practice; however, we would consider such changes to be 
unlikely or small in number). By selecting GP practices 
that do not refer patients to social prescribing within 
Newcastle upon Tyne, we will use the treatment assign-
ment rules (patients with T2D aged between 40 and 74) 
to generate a control group of patients from GPs outside 
the social prescribing referral network who would be 
eligible for treatment had social prescribing been avail-
able. Comparable control GP practices will be selected 
on the basis of practice Index of Multiple Deprivation 
scores to the social prescribing referral practices. In this 
case, the control group is exogenously determined: the 
individuals cannot select into treatment. This approach 
generates two possible control groups,  τ3a  and  τ3b , both 
of which will provide a different estimate of the treatment 
effect. With the larger samples sizes provided by control 
groups 2 and 3, we will be able to consider subgroup 
analyses (age, gender, ethnicity, presence of multimor-
bidity, service provider) to investigate whether there are 
some individuals who benefit more from treatment than 
others. Heterogeneity among treated groups is of serious 
concern to health policy-makers, and it may be that social 
prescribing has greater impact at different ages or among 
individuals with more comorbidity.
Our estimation strategy allows the estimation of a 
number of different average treatment effects that may or 
may not be affected by different levels of bias. We would 
expect:
  τOLS > τ1 ≥ τ2 ≥ τ3a > τ3b  
For continuous outcomes, naïve ordinary least squares 
estimation would give an estimated treatment effect 
of   ˆTOLS.  However, we would expect this estimate to over-
estimate any effect of treatment because individuals who 
are treated may be systematically different to patients 
who are untreated; for example, individuals who are 
untreated may have fewer comorbidities than the treated. 
Our intention-to-treat analysis ( τ3b ) should provide the 
smallest estimate of the treatment effect. Other estimates 
from the other control groups should lie between these 
upper and lower bounds. By highlighting the strengths 
and weaknesses of each estimated effect, our approach 
provides policy-makers with a much clearer under-
standing of the potential benefits that may arise from 
link-worker social prescribing. As a robustness test, we will 
undertake a falsification test where we will estimate the 
models outlined above using a pretreatment time period 
as the intervention date. In this case, any estimated treat-
ment effect should be zero. We will estimate models on 
complete cases and also weighted samples in order to 
account for attrition.
Work package 2
Cost-effectiveness analysis27 will be undertaken from the 
perspective of the healthcare provider. Separate analyses 
will be conducted on primary and secondary outcome 
measures. Detailed costs of the programme are available. 
Outcomes are measured 1 and 3 years after follow-up, so 
appropriate discounting will be applied. The comparator 
will be the standard treatment regime of the non-interven-
tion group. Effectiveness measures will come from WP1. 
Robustness will be investigated using sensitivity analysis. 
Outcome measures are incremental cost-effectiveness 
ratios demonstrating the ratio of the differences in the 
costs between the intervention and comparator and the 
difference in benefits.
research methods
The intervention will be compared with the standard 
treatment regime of the non-intervention group, and 
costs and benefits, where appropriate, will be discounted 
at 1.5% in line with the guidelines from the National 
institute for Health and Care Excellence for public 
health interventions.28 The effectiveness data will use 
the estimates from WP1 including EQ-5D-5L, which will 
be expanded by extrapolating broader health outcomes 
based on the literature linking T2D to quality-adjusted 
life years.29 The range of estimated effects from WP1 
will be applied in order to produce a range of cost-effec-
tiveness ratios that will demonstrate, using incremental 
cost-effectiveness ratios, the ranges where the interven-
tion is cost-effective (and potentially those ranges where 
it is not cost-effective).
Sensitivity of the results to changes in benefits and 
costs will be investigated by using the results from WP1. 
WP1 will provide a range of control groups that will 
provide different comparator groups, and also a range 
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of estimated treatment effects. The sensitivity of the 
economic evaluation to these different estimates will be 
investigated as part of the economic evaluation.
The incremental cost-effectiveness ratio will provide 
a range of estimates that can be used to inform deci-
sion-makers. The role of (economic) evaluation is not to 
provide an answer as to whether an intervention should 
be adopted or not—it is to provide information to the 
decision-maker so they can decide based on all of the 
available evidence.30
Work package 3
Over an 18-month period, interviews, participant obser-
vation and focus groups will yield a detailed account of 
the experiences of participants. Data will be used to build 
an understanding of how and why the intervention works 
and for whom, as well as reasons why the intervention 
does not work and for whom.
Recruitment and sample size: Between 18 and 24 key partic-
ipants (service users) will be recruited. Key participants 
will be purposively sampled on the basis of age, gender, 
ethnicity, employment status, social class, service provider, 
length of time engaged with the intervention and reason 
for remaining with/leaving the intervention. We plan to 
recruit friends and family opportunistically during partic-
ipant observation to provide supplementary data and we 
will undertake semistructured interviews with around 12 
family members and friends to explore their perspectives 
on the intervention. We will conduct focus groups with up 
to 22 link-workers.
Research methods
Each key participant will be followed from the begin-
ning to the end of fieldwork to allow us to follow their 
‘social prescribing journey’, including those who remain 
engaged with the service, those who ‘complete’ and those 
who drop out. We will observe their engagement with 
services, and explore practices within their families and 
social networks. At the start of fieldwork, key participants 
will participate in a semistructured interview exploring 
their experiences of the intervention. Each participant 
will be interviewed again in the final 6 months of field-
work to follow up their experiences of the intervention. 
Between the two interviews, opportunities for participant 
observation will be pursued as far as is feasible and will 
include spending time in participants’ homes and accom-
panying them to appointments with their link-worker and 
prescribed activities (eg, walking groups, volunteering 
activities, etc) depending on the preferences of the 
participant. Further episodes of participant observation 
will be pursued opportunistically. With at least 12 partici-
pants, particularly those who are less willing to invite the 
researcher into their lives for participant observation, we 
will use photo-elicitation interviews to supplement the 
standard interviews and provide a more complete and 
complex picture of the intervention.31 32 All link-workers 
will be invited to participate in focus groups. Further 
information on the delivery of Ways to Wellness will be 
obtained by joining intervention participants when they 
visit link-workers (where participants agree to this), which 
will include participant observation (‘hanging out’) in 
waiting rooms and staff rooms to build a picture of the 
‘culture’ of each provider.
Detailed field notes will be recorded after each episode 
of participant observation, in line with standard ethno-
graphic procedures. All interviews will be digitally 
recorded and subsequently transcribed verbatim. Qual-
itative data will comprise semistructured interview tran-
scripts and ethnographic field notes recording meetings 
with link-workers and other episodes of participant obser-
vation. Detailed field notes will record scenes encoun-
tered, pursuing meanings and reflecting on positionality, 
and will supplement interviews by describing contexts and 
information that is not audio-recorded, such as non-verbal 
communication. Line-by-line coding will be conducted to 
identify emerging themes. Analysis will involve synthe-
sising and theorising the data, and considering it in the 
context of other research.33 Participants’ photographs 
will also be analysed in their own right, following Pink’s 
suggestion that they can help the ethnographer to under-
stand how participants represent themselves, their envi-
ronments and experiences.34
Work package 4
Work package 4 integrates the findings of work packages 
1, 2 and 3. This is to enable a full interrogation of the 
compiled data for consistencies and differences, ensuring 
that the strengths of the complementary methods are 
fully integrated. Findings from each work package will 
be extracted and entered into a ‘convergence coding 
matrix’35 a mixed-methods analysis technique that 
enables identification of where there is agreement, 
partial agreement or dissonance between the findings of 
different study components.35 This facilitates an analysis 
of the reasons for agreement or differences between the 
various datasets, enabling the complementary strengths 
of the quantitative and qualitative methods to be fully 
examined.
Patient and public involvement
Research questions and outcome measures were informed 
by n=30 patients referred to Ways to Wellness via a qual-
itative interview study16 which explored their priorities, 
experiences and preferences. Link-workers delivering the 
intervention informed the study via a set of focus groups 
and interviews in which they discussed operationalising 
the intervention.
Results will be disseminated to participants via Ways 
to Wellness, link-workers, the study website and through 
social media. For participants in the qualitative study, 
those findings will be disseminated via face-to-face meet-
ings, printed literature and the study website.
summary
This study is the first of its kind to take a mixed-methods 
approach that combines quantitative quasi-experimental 
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methods, economic assessment and ethnography to assess 
the impact and value for money of a social prescribing 
intervention. The study is timely and relevant to the 
NHS and the voluntary and community sectors. Three 
elements make it distinctive.
First is the use of quasi-experimental methods. The 
social prescribing intervention can be considered as a 
natural experiment; that is, assignment to treatment is 
non-random by means of administrative selection.36 37 
Although natural experimental methods are increasingly 
being used to evaluate public health interventions,37 
applying these methods to measuring the impact of social 
prescribing is unique. Natural experimental methods 
divide the population into a treated and an untreated 
group, allowing the application of regression methods to 
estimate treatment effects. These methods have an advan-
tage over randomised controlled design methods in that 
they can be applied to the evaluation of interventions that 
have already started, where the intervention is not under 
the control of the researcher and blinding assumptions 
that would usually be required for conducting a robust 
RCT would be violated.
A second distinctive aspect of this study is the use of 
ethnography. While standard interview approaches, as 
used earlier,16 are informative and valuable, ethnography 
is a more powerful tool to uncover how the intervention 
plays out in the complex daily lives and practices of partic-
ipants. The use of observation, interviews, focus groups 
and photo-elicitation techniques provides contrasts 
between the ‘life that is told’ (accessed via interviews) 
and the ‘life that is lived’ (accessed via participant obser-
vation).38 Ethnography enables examination of how the 
intervention fits in with the constraints of comorbidity, 
domestic routines and habits, (un)employment and the 
welfare system, and how the meanings of practices such 
as eating, exercising or taking part in community activ-
ities influence participants’ engagement. Wider imple-
mentation will be enhanced by an understanding of how 
change is brought about, experienced and maintained.39 
We will also examine inevitable variation in the delivery of 
the intervention (within the constraints of the protocol) 
by exploring any differences in the experiences of partici-
pants assigned to the two different provider organisations.
Third, we combine natural experimental methods and 
ethnography in a distinctive mixed-methods approach. 
These work packages will run in parallel, with the find-
ings from one approach informing the other, and vice 
versa. The longitudinal nature of the quantitative data 
enables us to quantify impacts between different groups 
over time; the ethnography enables an approach to field-
work and data analysis that permits deep and recurrent 
questioning. Integrating the results35 will enable multilay-
ered interrogation of differences and similarities gener-
ating greater insights into what has been identified and 
also to probe deeply into why.
There are challenges in generalising the findings 
to other settings and providing sufficiently detailed 
evidence for decision-makers to enact policy changes and 
implement appropriate services. Maximising the general-
isability of the study findings requires both quantitative 
data about health improvement associated with the inter-
vention and its associated costs, and in-depth qualitative 
data about the operationalisation of the intervention. 
There are several models of social prescribing and it is,
“… being implemented across the UK with local varia-
tions according to level and source of funding, model of 
commissioning, the targeting and identification of service 
users, geographical coverage, referral sources and the 
breadth of ‘prescribed’ activities. ” (Dayson 2017, p. 91)
Although social prescribing has become a more ‘main-
stream’ intervention in the UK since 2012,40 commis-
sioners and practitioners require robust evidence to guide 
the implementation of best practice social prescribing.
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